Drug Development

Agnes Shanley is senior editor of Pharmaceutical Technology.

Articles

CMO executives share their opinions on where outsourcing is going and what is driving market change.

The Future of Contract Services

After launching a new mammalian cell platform, FUJIFILM Diosynth Biotechnologies U.S.A., has acquired fast-track vaccine manufacturing knowhow and a major presence in Texas’ emerging biocorridor with Kalon, its first acquisition.

FUJIFILM's New Biopharm Game Plan

New drugs submitted for approval in Europe have 18 months to comply with new elemental impurities guidelines.

EMA Sets Elemental Impurities Implementation Dates

Randi Hernandez was science editor at Pharmaceutical Technology from September 2014 to May 2017.

Catalent announced that it would partner with Mitsubishi Gas Chemical Company, and its subsidiary MGC Pharma, to promote GPEx technology, a high-titer vector for stable mammalian cell lines.

Catalent and MGC Pharma Partner for Production of Cell Lines

USP establishes Jan. 1, 2018 as the implementation date for its elemental impurities guidelines for existing drugs.

USP Elemental Impurities Implementation Set for January 2018

Adeline Siew is editor for Pharmaceutical Technology Europe. She is also science editor for Pharmaceutical Technology.

Innovative Excipients in Solid-Dosage Manufacturing

Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.

Changing dynamics of the pharmaceutical industry are driving demand.

API Custom Manufacturing Outlook: More Growth in 2015

Analytical and procedural deficiencies result in FDA warning letter for Novacyl Wuxi Pharmaceutical.

Chinese API and Drug Manufacturer Issued Warning Letter

Protein Sciences will evaluate sourcing Flublok from its Japanese licensee, UMN Pharma, which already runs a large-scale facility for the vaccine.

Protein Sciences Considers Sourcing Flublok From Japan

FDA approves treatments for new diseases and drugs that operate by new mechanisms.

APIs and Excipients